MNOV (MediciNova) Issuance of Debt: $0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MNOV MediciNova Inc MNOV
30 GF Score
Price $1.32
! 2 Warning Signs
View Full Analysis

What is MediciNova Issuance of Debt?

MediciNova MNOV +0.77% 30 Issuance of Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates MNOV with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

MediciNova's Issuance of Debt for the three months ended in Mar. 2026 was $0.00 Mil.

MediciNova's Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

MediciNova Issuance of Debt Related Terms

MediciNova Issuance of Debt Historical Data

* Premium members only.

The historical data trend for MediciNova's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MediciNova Issuance of Debt Chart

MediciNova Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MediciNova Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MNOV
30GF Score
MediciNova Inc MNOV
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MediciNova Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of $0.00 Mil mean?
MediciNova (MNOV) has a Issuance of Debt of $0.00 Mil as of Mar. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on MediciNova and its competitors.
Is MediciNova's Issuance of Debt too high?
MediciNova's current Issuance of Debt is $0.00 Mil. Overall, MediciNova has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does MediciNova's Issuance of Debt compare to TCRX and PMVP?
MediciNova's Issuance of Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on MediciNova and its competitors. MediciNova's current Issuance of Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediciNova stock overvalued right now?
MediciNova (MNOV) has a current Issuance of Debt of $0.00 Mil. The current Issuance of Debt is $0.00 Mil. MediciNova's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For MediciNova (MNOV), the current Issuance of Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MediciNova Business Description

Other Exchanges 4875:Japan
Address 4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
30GF Score

Get the complete analysis for MNOV

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.32
Price